

No. 23-2366

**UNITED STATES COURT OF APPEALS
FOR THE SEVENTH CIRCUIT**

K.C., et al.,

Plaintiffs-Appellees,

v.

INDIVIDUAL MEMBERS OF THE MEDICAL LICENSING BOARD OF INDIANA, et
al.,

Defendants-Appellants.

On Appeal from the United States District Court
for the Southern District of Indiana
Case No. 1:23-cv-00595-JPH-KMB

**BRIEF OF ALLIANCE DEFENDING FREEDOM AS AMICUS
CURIAE IN SUPPORT OF APPELLANTS AND FOR REVERSAL**

JACOB P. WARNER
ALLIANCE DEFENDING FREEDOM
15100 N. 90th Street
Scottsdale, AZ 85260
(480) 444-0020
jwarner@ADFlegal.org

JOHN J. BURSCH
JAMES A. CAMPBELL
ALLIANCE DEFENDING FREEDOM
440 First Street NW
Suite 600
Washington, DC 20001
(616) 450-4235
jbursch@ADFlegal.org
jcampbell@ADFlegal.org

Attorneys for Amicus Curiae

APPEARANCE & CIRCUIT RULE 26.1 DISCLOSURE STATEMENT

Appellate Court No: 23-2366

Short Caption: K.C., et al. v. Individual Members of the Medical Licensing Board of Indiana, et al.

To enable the judges to determine whether recusal is necessary or appropriate, an attorney for a non-governmental party, amicus curiae, intervenor or a private attorney representing a government party, must furnish a disclosure statement providing the following information in compliance with Circuit Rule 26.1 and Fed. R. App. P. 26.1.

The Court prefers that the disclosure statements be filed immediately following docketing; but, the disclosure statement must be filed within 21 days of docketing or upon the filing of a motion, response, petition, or answer in this court, whichever occurs first. Attorneys are required to file an amended statement to reflect any material changes in the required information. The text of the statement must also be included in the front of the table of contents of the party's main brief. **Counsel is required to complete the entire statement and to use N/A for any information that is not applicable if this form is used.**

PLEASE CHECK HERE IF ANY INFORMATION ON THIS FORM IS NEW OR REVISED AND INDICATE WHICH INFORMATION IS NEW OR REVISED.

(1) The full name of every party that the attorney represents in the case (if the party is a corporation, you must provide the corporate disclosure information required by Fed. R. App. P. 26.1 by completing item #3):
Alliance Defending Freedom

(2) The names of all law firms whose partners or associates have appeared for the party in the case (including proceedings in the district court or before an administrative agency) or are expected to appear for the party in this court:
Alliance Defending Freedom

(3) If the party, amicus or intervenor is a corporation:

i) Identify all its parent corporations, if any; and

N/A

ii) list any publicly held company that owns 10% or more of the party's, amicus' or intervenor's stock:

N/A

(4) Provide information required by FRAP 26.1(b) – Organizational Victims in Criminal Cases:

N/A

(5) Provide Debtor information required by FRAP 26.1 (c) 1 & 2:

N/A

Attorney's Signature: s/ John J. Bursch Date: August 28, 2023

Attorney's Printed Name: John J. Bursch

Please indicate if you are *Counsel of Record* for the above listed parties pursuant to Circuit Rule 3(d). Yes No

Address: 440 First Street NW, Suite 600

Washington, DC 20001

Phone Number: (616) 45-4235 Fax Number: _____

E-Mail Address: jbursch@adfllegal.org

Appellate Court No: 23-2366

Short Caption: K.C., et al. v. Individual Members of the Medical Licensing Board of Indiana, et al.

To enable the judges to determine whether recusal is necessary or appropriate, an attorney for a non-governmental party, amicus curiae, intervenor or a private attorney representing a government party, must furnish a disclosure statement providing the following information in compliance with Circuit Rule 26.1 and Fed. R. App. P. 26.1.

The Court prefers that the disclosure statements be filed immediately following docketing; but, the disclosure statement must be filed within 21 days of docketing or upon the filing of a motion, response, petition, or answer in this court, whichever occurs first. Attorneys are required to file an amended statement to reflect any material changes in the required information. The text of the statement must also be included in the front of the table of contents of the party's main brief. **Counsel is required to complete the entire statement and to use N/A for any information that is not applicable if this form is used.**

PLEASE CHECK HERE IF ANY INFORMATION ON THIS FORM IS NEW OR REVISED AND INDICATE WHICH INFORMATION IS NEW OR REVISED.

(1) The full name of every party that the attorney represents in the case (if the party is a corporation, you must provide the corporate disclosure information required by Fed. R. App. P. 26.1 by completing item #3):

Alliance Defending Freedom

(2) The names of all law firms whose partners or associates have appeared for the party in the case (including proceedings in the district court or before an administrative agency) or are expected to appear for the party in this court:

Alliance Defending Freedom

(3) If the party, amicus or intervenor is a corporation:

i) Identify all its parent corporations, if any; and

N/A

ii) list any publicly held company that owns 10% or more of the party's, amicus' or intervenor's stock:

N/A

(4) Provide information required by FRAP 26.1(b) – Organizational Victims in Criminal Cases:

N/A

(5) Provide Debtor information required by FRAP 26.1 (c) 1 & 2:

N/A

Attorney's Signature: s/ Jacob P. Warner Date: August 28, 2023

Attorney's Printed Name: Jacob P. Warner

Please indicate if you are *Counsel of Record* for the above listed parties pursuant to Circuit Rule 3(d). Yes No

Address: 15100 N. 90th Street

Scottsdale, AZ 85260

Phone Number: (480) 444-0020 Fax Number: (480) 444-0028

E-Mail Address: jwarner@adflegal.org

APPEARANCE & CIRCUIT RULE 26.1 DISCLOSURE STATEMENT

Appellate Court No: 23-2366

Short Caption: K.C., et al. v. Individual Members of the Medical Licensing Board of Indiana, et al.

To enable the judges to determine whether recusal is necessary or appropriate, an attorney for a non-governmental party, amicus curiae, intervenor or a private attorney representing a government party, must furnish a disclosure statement providing the following information in compliance with Circuit Rule 26.1 and Fed. R. App. P. 26.1.

The Court prefers that the disclosure statements be filed immediately following docketing; but, the disclosure statement must be filed within 21 days of docketing or upon the filing of a motion, response, petition, or answer in this court, whichever occurs first. Attorneys are required to file an amended statement to reflect any material changes in the required information. The text of the statement must also be included in the front of the table of contents of the party's main brief. Counsel is required to complete the entire statement and to use N/A for any information that is not applicable if this form is used.

PLEASE CHECK HERE IF ANY INFORMATION ON THIS FORM IS NEW OR REVISED AND INDICATE WHICH INFORMATION IS NEW OR REVISED.

(1) The full name of every party that the attorney represents in the case (if the party is a corporation, you must provide the corporate disclosure information required by Fed. R. App. P. 26.1 by completing item #3): Alliance Defending Freedom

(2) The names of all law firms whose partners or associates have appeared for the party in the case (including proceedings in the district court or before an administrative agency) or are expected to appear for the party in this court: Alliance Defending Freedom

(3) If the party, amicus or intervenor is a corporation:

i) Identify all its parent corporations, if any; and

N/A

ii) list any publicly held company that owns 10% or more of the party's, amicus' or intervenor's stock:

N/A

(4) Provide information required by FRAP 26.1(b) – Organizational Victims in Criminal Cases:

N/A

(5) Provide Debtor information required by FRAP 26.1 (c) 1 & 2:

N/A

Attorney's Signature: s/ James A. Campbell Date: August 28, 2023

Attorney's Printed Name: James A. Campbell

Please indicate if you are Counsel of Record for the above listed parties pursuant to Circuit Rule 3(d). Yes No

Address: 440 First Street NW, Suite 600

Washington, DC 20001

Phone Number: (202) 393-8690 Fax Number:

E-Mail Address: jcampbell@adflegal.org

TABLE OF CONTENTS

Corporate Disclosure Statement.....	i
Table of Authorities.....	iv
Identity and Interest of Amicus Curiae.....	1
Introduction.....	2
Argument.....	3
I. Rational-basis review applies, and the Act easily satisfies both rational-basis and intermediate scrutiny.....	3
A. The Act protects children from unproven drug treatments no matter how they identify.	4
B. The Act reasonably advances its important goal of protecting children from risky drug treatments.	8
1. The Endocrine Society guidelines and WPATH standards of care lack evidence-based support.	8
2. Systematic reviews have shown insufficient evidence to use puberty blockers and cross-sex hormones to treat minors with gender dysphoria.....	11
3. Using puberty blockers and cross-sex hormones to treat minors with gender dysphoria has no proven benefits and poses substantial risk.	13
4. Drug companies have not sought regulatory approval for puberty blockers and cross-sex hormones to treat minors with gender dysphoria.....	19
5. That puberty blockers and cross-sex hormones are used to treat different physical illness does not make them safe to treat gender dysphoria.....	21

6.	Consistent with evidence-based medicine, this Court should credit experts based mainly on their analysis of published evidence.....	23
II.	This Court should allow state legislatures to decide this difficult medical issue rife with uncertainty and so avoid miring courts further in constitutionalized medicine.	25
	Conclusion	26
	Certificate of Compliance.....	28
	Certificate of Service	29

TABLE OF AUTHORITIES

Cases

<i>Brown v. Gilmore</i> , 533 U.S. 1301 (2001)	3
<i>Dobbs v. Jackson Women’s Health Organization</i> , 142 S. Ct. 2228 (2022)	26
<i>Eknes-Tucker v. Governor of Alabama</i> , No. 22-11707, 2023 WL 5344981 (11th Cir. Aug. 21, 2023)	7, 25
<i>GEFT Outdoor, LLC v. City of Westfield</i> , 39 F.4th 821 (7th Cir. 2022)	4
<i>Gonzales v. Carhart</i> , 550 U.S. 124 (2007)	25, 26
<i>Lux v. Rodrigues</i> , 561 U.S. 1306 (2010)	3
<i>New York v. Ferber</i> , 458 U.S. 747 (1982)	7, 25
<i>Otto v. City of Boca Raton</i> , 981 F.3d 854 (11th Cir. 2020)	25
<i>Reed v. Reed</i> , 404 U.S. 71 (1971)	4
<i>Roe v. Wade</i> , 410 U.S. 113 (1973)	26
<i>San Antonio Independent School District v. Rodriguez</i> , 411 U.S. 1 (1973)	4
<i>Tagami v. City of Chicago</i> , 875 F.3d 375 (7th Cir. 2017)	4
<i>Tuan Anh Nguyen v. INS</i> , 533 U.S. 53 (2001)	4

Winter v. Natural Resource Defense Council, Inc.,
555 U.S. 7 (2008) 3

Statutes

21 U.S.C. § 355 19, 20

Ind. Code 25-1-22-1 1

Other Authorities

Alexis D. Light et al., *Transgender Men Who Experienced
Pregnancy After Female-to-Male Gender Transitioning*, 124:6
Obstetrics & Gynecology 1120 (2014) 16

American Psychiatric Association, *Diagnostic & Statistical Manual
of Mental Disorders* (5th ed. 2013) 5

Annette L. Cantu et al., *Changes in Anxiety & Depression from
Intake to First Follow-Up Among Transgender Youth in a
Pediatric Endocrinology Clinic*, 5:3 *Transgender Health* 196
(2020) 15

C. Haupt et al., *Cochrane Library, Antiandrogen or estradiol
treatment or both during hormone therapy in transitioning
transgender women (Review)* (2020) 12

C.M. Wiepjas et al., *Trends in suicide death risk in transgender
people: results from the Amsterdam Cohort of Gender
Dysphoria study (1972-2017)*, 141 *Acta Psychiatrica
Scandinavica* 486 (2020) 14

Care of children & adolescents with gender dysphoria,
Socialstyrelsen (2022) 11

Cecilia Dhejne et al., *Long-Term Follow-Up of Transsexual Persons
Undergoing Sex Reassignment Surgery: Cohort Study in
Sweden*, 6:2 *PLOS ONE* 1 (2011) 14, 18

Chad Terhune et al., *As more transgender children seek medical care, families confront many unknowns*, Reuters (Oct. 6, 2022) 21

Clinical Research Versus Medical Treatment, FDA (2018) 12

David L. Sackett et al., *Evidence based medicine: what it is and what it isn't*, 312 BMJ 71 (1996) 23

Denmark Joins the List of Countries That Have Sharply Restricted Youth Gender Transitions, SEGM (Aug. 17, 2023) 12

Diane Chen et al., *Consensus Parameter: Research Methodologies to Evaluate Neurodevelopmental Effects of Pubertal Suppression in Transgender Youth*, 5:4 Transgender Health 246 (2020) 15

E. Abbruzzese et al., *The Myth of ‘Reliable Research’ in Pediatric Gender Medicine: A critical evaluation of the Dutch Studies—and research that has followed*, J. Sex & Marital Therapy (2023) 6, 7

E. Coleman et al., *Standards of Care for the Health of Transgender and Gender Diverse People, Version 8*, 23 Int’l J. Transgender Health S1 (2022)..... 10

E. Elenis et al., *Early initiation of anti-androgen treatment is associated with increased probability of spontaneous conception leading to childbirth in women with polycystic ovary syndrome: a population-based multiregistry cohort study in Sweden*, 36:5 Human Reproduction 1427 (2021) 22

Elizabeth Hisle-Gorman et al., *Mental Healthcare Utilization of Transgender Youth Before & After Affirming Treatment*, 18 J. Sexual Med. 1444 (2021) 15

Endo Reports Fourth-Quarter & Full-Year 2021 Financial Results, ENDO (2022) 20

Evidence review: Gender-affirming hormones for children & adolescents with gender dysphoria, NICE (2020)..... 11, 14, 17, 18

Evidence review: Gonadotrophin releasing hormone analogues for children & adolescents with gender dysphoria, NICE (2020) 11, 14, 16

Expert Q&A: Gender Dysphoria, Am. Psychiatric Ass’n 5

Financial Release, AbbVie (2021) 20

Gordon Guyatt et al., *GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes*, 66 *J. Clinical Epidemiology* 151 (2013) 9

Gordon Guyatt et al., *Users’ Guides to the Medical Literature* (McGraw Hill Education, 3rd ed. 2015) 8, 23

Henk Asscheman et al., *A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones*, 164:4 *Eur. J. Endocrinology* 635 (2011) 19

Howard Balshem et al., *GRADE guidelines: 3. Rating the quality of evidence*, 64 *J. Clinical Epidemiology* 401 (2011) 8

Icahn Sch. of Med., *State of the Art: Transgender Hormone Care*, YouTube (Feb. 15, 2019) 10

Implementing advice from the Cass Review, NHS (2023) 11

James M. Cantor, *American Academy of Pediatrics policy and trans- kids: Fact-checking*, *Sexology Today!* (2018) 6

Jay McNeil et al., *Suicide in Trans Populations: A Systematic Review of Prevalence and Correlates*, 4:3 *Psychology of Sexual Orientation & Gender Diversity* 341 (2017) 14

Jeffrey C. Andrews et al., *GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength*, 66 *J. Clinical Epidemiology* 726 (2013) 9

Jennifer Block, *Gender dysphoria in young people is rising—and so is professional disagreement*, *BMJ* (2023) 9, 10

Kellan E. Baker et al., *Hormone Therapy, Mental Health, & Quality of Life Among Transgender People: A Systematic Review*, 5:4 J. Endocrine Soc’y 1 (2021) 14

Kenneth J. Zucker, *Debate: Different strokes for different folks*, Child & Adolescent Mental Health (2019) 6

Knudson, G., & De Sutter, P., *Fertility options in transgender and gender diverse adolescents*. 96(10) Acta obstetricia et gynecologica Scandinavica 1269 (2017)..... 16

Kristina R. Olson et al., *Gender Identity 5 Years After Social Transition*, 150:2 Pediatrics 3 (2022)..... 6

Laura E. Kuper et al., *Body Dissatisfaction & Mental Health Outcomes of Youth on Gender-Affirming Hormone Therapy*, 145:4 Pediatrics 1 (2020)..... 14

Lisa Littman, *Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria*, PLOS ONE (2018) 7

Medical treatment methods for dysphoria associated with variations in gender identity in minors – recommendation, Council for Choices in Health Care in Finland (2020)..... 11

Melinda Chen & Erica A. Eugster, *Central Precocious Puberty: Update on Diagnosis & Treatment*, 17:4 Paediatr Drugs 273 (2015) 22

Michael Biggs, *The Dutch Protocol for Juvenile Transsexuals: Origins & Evidence*, J. Sex & Marital Therapy (2022) 18

Paula Amato, *Fertility options for transgender persons*, UCFS (June 17, 2016) 17

Polly Carmichael et al., *Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK*, 16:2 PLOS ONE 1 (2021)..... 15

Press Release, U.S. Atty’s Off., *Abbott Laboratories and AbbVie Inc. to Pay \$25 Million to Resolve False Claims Act Allegations of Kickbacks and Off-Label Marketing of the Drug TriCor* (Oct. 26, 2018) 20

Press Release, U.S. Dep’t Justice, *Pfizer to Pay \$2.3 Billion for Fraudulent Marketing* (Sept. 2, 2009) 20

Press Release, U.S. Dep’t of Justice, *Endo Pharmaceuticals and Endo Health Solutions to Pay \$192.7 Million to Resolve Criminal and Civil Liability Relating to Marketing of Prescription Drug Lidoderm for Unapproved Uses* (Feb. 21, 2014) 20

Riittakerttu Kaltiala et al., *Adolescent development and psychosocial functioning after starting cross-sex hormones for gender dysphoria*, 74:3 *Nordic J. Psychiatry* 213 (2020)..... 15

Riittakerttu Kaltiala et al., *Youth Gender Transition is Pushed Without Evidence*, *Wall St. J.*, July 13, 2023..... 13

Riittakerttu Kaltiala-Heino et al., *Two years of gender identity service for minors: overrepresentation of natal girls with severe problems in adolescent development*, 9 *Child & Adolescent Psychiatry & Mental Health* 6 (2015)..... 7

Romina Brignardello-Petersen & Wojtek Wiercioch, *Effects of gender affirming therapies in people with gender dysphoria: evaluation of the best available evidence* (2022) 12

Stephen B. Levine et al., *Reconsidering Informed Consent for Trans-Identified Children, Adolescents, & Young Adults*, *J. Sex & Marital Therapy* (2022) 18

The Cass Review, *Independent review of gender identity services for children and young people: Interim report* (2022)..... 5, 7, 16, 17

Understanding Unapproved Use of Drugs “Off Label,” U.S. Food & Drug Admin. (2018)..... 19

Wylie C. Hembree et al., *Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline*, 102:11 J. Clinical Endocrinol Metab. 3869 (2017)..... passim

Regulations

21 C.F.R. § 202.1 20

21 C.F.R. § 314.54 19

21 C.F.R. § 314.70 19

IDENTITY AND INTEREST OF AMICUS CURIAE¹

Alliance Defending Freedom is the world’s largest law firm dedicated to religious freedom, free speech, the sanctity of life, parental rights, and marriage and family. Because the law should protect life—including from irreversible and unproven medical interventions—ADF advocates for laws that protect children from drug treatments that could potentially harm them for life.

ADF is deeply concerned about the use of puberty blockers and cross-sex hormones for children with gender dysphoria. Systematic reviews have shown insufficient evidence to support such use. Many studies even suggest these interventions are dangerous. This has led many European nations and American states to forbid puberty blockers and cross-sex hormones for children with gender dysphoria. ADF believes such caution is best, given the high stakes and uncertain science.

ADF has served as co-counsel defending states that protect children from potentially dangerous drug interventions, *e.g.*, *Boe v. Marshall*, No. 2:22-cv-184-LCB (M.D. Ala.), and submits this brief supporting Indiana’s Senate Enrolled Act 480, codified at Ind. Code 25-1-22-1 *et seq.* (“the Minors Protection Act” or simply the “Act”).

¹No counsel for a party authored this brief in whole or in part, and no person other than amicus and its counsel made any monetary contribution intended to fund the preparation or submission of this brief. All counsel were timely notified of this brief and consented to its filing.

INTRODUCTION

Indiana seeks to protect children from unproven drug treatments that risk permanent harm. It enacted the Minors Protection Act to regulate puberty blockers and cross-sex hormones for children experiencing gender dysphoria. After examining the medical literature and best practices around the world, Indiana found such drug use is harmful. At minimum, the State found that using these drugs is reckless because they are experimental, unsupported by high-quality evidence, and pose unknown risks. Respondents challenge this protection, seeking a constitutional right to inject children with experimental drugs.

The district court preliminarily enjoined the Act, holding that while Indiana has a compelling interest in protecting children, the Act fails heightened scrutiny because it could have been drawn more narrowly. That ruling wrongly requires the Act to satisfy strict scrutiny. At most, the State need only show that the Act reasonably advances its significant interest in protecting children. The Act easily satisfies that test. No high-quality evidence supports using puberty blockers and cross-sex hormones to treat children with gender dysphoria, and multiple studies suggest that such interventions are potentially dangerous. Regulating these interventions is both reasonable and critical to protecting children.

Notably, courts give legislatures wide discretion to pass legislation when there is medical and scientific uncertainty. Just last year, the Supreme Court reversed a 50-year-old precedent constitutionalizing a right

to abortion, recognizing it had improperly withheld judicial restraint on a critical social issue. This Court should not repeat that error here by constitutionalizing a new right to unproven drug treatments.

Accordingly, ADF asks this Court to reverse the ruling below and allow Indiana to continue protecting its children.

ARGUMENT

An injunction “is an extraordinary remedy never awarded as of right.” *Winter v. Nat. Res. Def. Council, Inc.*, 555 U.S. 7, 24 (2008). It “may only be awarded upon a *clear showing* that the plaintiff” deserves it. *Id.* at 22 (emphasis added). This is especially true when plaintiffs seek to enjoin the “enforcement of a presumptively valid state statute,” *Brown v. Gilmore*, 122 S. Ct. 1, 1 (2001) (Rehnquist, C.J., in chambers), which “demands” unusually strong “justification.” *Lux v. Rodrigues*, 561 U.S. 1306, 1307 (2010) (Roberts, C.J., in chambers). To obtain a preliminary injunction, Plaintiffs must at least prove they are “likely to succeed on the merits.” *Winter*, 555 U.S. at 20. Plaintiffs have not done so here because while rational-basis review applies, the Act satisfies even intermediate scrutiny by reasonably protecting children from unproven drugs.

I. Rational-basis review applies, and the Act easily satisfies both rational-basis and intermediate scrutiny.

Statutory classifications are typically valid if they rationally advance a legitimate interest. *San Antonio Indep. Sch. Dist. v. Rodriguez*,

411 U.S. 1, 55 (1973). Closer scrutiny applies when laws implicate suspect or quasi-suspect classes. *Reed v. Reed*, 404 U.S. 71, 76 (1971). Laws that implicate a quasi-suspect class like sex must advance an “important” goal through “substantially related” means. *Tuan Anh Nguyen v. INS*, 533 U.S. 53, 60 (2001). While the court below enjoined the Act saying Indiana could have used “less-restrictive means,” Order Granting in Part Pls.’ Mot. for Prelim. Inj. (Order) 27, *K.C. v. The Individual Members of the Med. Licensing Bd. of Ind.*, No. 1:23-cv-00595-JPH-KMB (June 16, 2023), ECF No. 67, only a reasonable fit is required—not a “perfect” one, *GEFT Outdoor, LLC v. City of Westfield*, 39 F.4th 821, 825 (7th Cir. 2022); see *Tagami v. City of Chicago*, 875 F.3d 375, 380 (7th Cir. 2017). Rational-basis review applies here because the Act does not target a suspect or quasi-suspect class; it regulates drugs used on minors of both sexes. Regardless, the Act satisfies even intermediate scrutiny.

A. The Act protects children from unproven drug treatments no matter how they identify.

Indiana enacted the Minors Protection Act to protect the health and welfare of minors. Defs.’ Mem. in Opp’n to Pls.’ Mot. for Prelim. Inj. 22-29, *K.C. v. The Individual Members of the Med. Licensing Bd. of Ind.*, No. 1:23-cv-00595-JPH-KMB (June 2, 2023), ECF No. 54. The State asserts that using puberty blockers and cross-sex hormones to treat children with gender dysphoria is unsafe. *Id.* at 22. Such intervention increases the risk of depression, sexual dysfunction, cardiovascular disease, stroke,

breast cancer, liver disease, and more. *Id.* at 23. At minimum, Indiana asserts that giving children these drugs is reckless because the drugs are “unproven” and “experimental,” children cannot effectively consent to them, and they may inflict “irreversible” damage. *Id.* at 28.

The Act reasonably protects *all* children. While Plaintiffs argue that the Act “exclusively targets transgender people,” the Act evenly protects all children. Mem. in Supp. of Mot. for Prelim. Inj. (MPI) 20, *K.C. v. The Individual Members of the Med. Licensing Bd. of Ind.*, No. 1:23-cv-00595-JPH-KMB (Apr. 21, 2023), ECF No. 27. Gender dysphoria is a recognized mental health condition. Am. Psychiatric Ass’n, *Diagnostic & Statistical Manual of Mental Disorders* 512 (5th ed. 2013). It requires six-month “marked incongruence between one’s experienced/expressed gender and assigned gender” that is “associated with clinically significant distress.” *Id.* In contrast, transgender *identification* is not a mental disorder. People can identify as transgender without suffering from gender dysphoria. *Expert Q&A: Gender Dysphoria*, Am. Psychiatric Ass’n, <https://perma.cc/3YJ4-F2A2> (last accessed July 13, 2023).

What’s more, adolescent gender dysphoria often does not lead to adult transgender identification. Until recently, most minors presenting with gender dysphoria were pre-pubescent males. The Cass Review, *Independent review of gender identity services for children and young people: Interim report* 32 (2022), <https://perma.cc/9CT5-J6NU>. The Dutch protocol analyzed this population exclusively. E. Abbruzzese et al., *The*

Myth of 'Reliable Research' in Pediatric Gender Medicine: A critical evaluation of the Dutch Studies—and research that has followed 12, J. Sex & Marital Therapy (2023), App.94. With psychotherapy alone, the study showed the vast majority of these children ceased to experience gender dysphoria during adolescence and identified with their natal sex as an adult. Wylie C. Hembree et al., *Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline*, 102:11 J. Clinical Endocrinol Metab. 3869, 3879 (2017), App.726; James M. Cantor, *American Academy of Pediatrics policy and trans- kids: Fact-checking* 1, Sexology Today! (2018), App. 464.

Such desistence is good. The affected individual no longer has a mental health condition and needs no more treatment. While Plaintiffs say these lifetime drugs “are safe and effective,” Pls.’ Reply Mem. in Supp. of Mot. for Prelim. Inj. (MPI Reply) 9, *K.C. v. The Individual Members of the Med. Licensing Bd. of Ind.*, No. 1:23-cv-00595-JPH-KMB (June 12, 2023), ECF No. 59, the Act seeks to protect children from “iatrogenic” intervention—treatments that *create* disease rather than cure it. Kenneth J. Zucker, *Debate: Different strokes for different folks* 1-2, Child & Adolescent Mental Health (2019), App.517-18. This intervention substantially risks disrupting the ordinary resolution of gender dysphoria. Children subject to it are far more likely to *persist* in experiencing gender dysphoria than those who aren’t. Kristina R. Olson et al., *Gender Identity 5 Years After Social Transition*, 150:2 Pediatrics 3 (2022), App.521. So

early transition “is not a neutral” decision. Cass Review 38, 62-63. The Act allows space for children’s gender dysphoria to resolve.

This space is critical because a new group dominates gender clinics: mid-adolescent females *without* childhood history of gender discordance. Riittakerttu Kaltiala-Heino et al., *Two years of gender identity service for minors: overrepresentation of natal girls with severe problems in adolescent development*, 9 *Child & Adolescent Psychiatry & Mental Health* 6 (2015), App.615; Lisa Littman, *Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria* 3, *PLOS ONE* (2018), <https://perma.cc/E8ZH-FWP6>; Cass Review 38. Early research did not study this group. Abbruzzese, *supra*, at 12, App.94. And modern research lags because this group is newly developing. Littman, *supra*, at 3. But as with males, nothing suggests this group will necessarily identify as transgender in adulthood. Caution is critical.

The Act aims to protect Indiana children, no matter how they identify. So it does not distinguish based on a suspect or quasi-suspect classification. *Eknes-Tucker v. Governor of Alabama*, No. 22-11707, 2023 WL 5344981, at *15 (11th Cir. Aug. 21, 2023) (A law regulating “specific medical interventions for [all] minors [is] not one that classifies on the basis of any suspect characteristic under the Equal Protection Clause.”). And Indiana’s goal of protecting children is both legitimate and “compelling.” *New York v. Ferber*, 458 U.S. 747, 756-57 (1982).

B. The Act reasonably advances its important goal of protecting children from risky drug treatments.

1. The Endocrine Society guidelines and WPATH standards of care lack evidence-based support.

Rejecting Indiana’s concerns about unproven drug interventions, Plaintiffs invoke the WPATH and Endocrine Society guidelines to support nixing the Act. MPI at 6-10. But “optimal clinical decision making requires” support “from systematic summaries” based on high-quality evidence. Gordon Guyatt et al., *Users’ Guides to the Medical Literature* 10 (McGraw Hill Education, 3rd ed. 2015). The Endocrine Society guidelines and WPATH standards of care lack such evidentiary support.

The GRADE method is widely accepted for rating available medical evidence. *Id.* at 16. It ranks the evidence into four tiers. High-quality evidence means the “true effect [of intervention] lies close to that of the estimate.” Howard Balshem et al., *GRADE guidelines: 3. Rating the quality of evidence*, 64 *J. Clinical Epidemiology* 401, 404 (2011), App.461. Moderate-quality evidence means the “true effect is likely to be close to the estimate..., but [it may be] substantially different.” *Id.* Low-quality evidence means the “true effect may be substantially different from the estimate.” *Id.* And very-low-quality evidence means the “true effect is likely to be substantially different from the estimate.” *Id.*

When applied properly, the GRADE method “achieves explicit and transparent judgment” by requiring evaluators to disclose all evidence

and reasons supporting their rating. Gordon Guyatt et al., *GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes*, 66 *J. Clinical Epidemiology* 151, 155 (2013), App.455. In general, strong recommendations should *not* be made based on low-quality evidence—only when “a panel would have a low level of regret if [later] evidence showed that their recommendation was misguided.” Jeffrey C. Andrews et al., *GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength*, 66 *J. Clinical Epidemiology* 726, 731 (2013), App.490.

The Endocrine Society guidelines are not evidence-based. They lack support from systematic evidentiary reviews on key questions, including whether the recommended treatments ease gender dysphoria, improve mental health, affect brain development, or impact fertility. Hembree, *supra*, at 3873, App.720; Jennifer Block, *Gender dysphoria in young people is rising—and so is professional disagreement* 2-3, *BMJ* (2023), App.496-97. The authors did not systematically list the evidence supporting their recommendations or justify their evidence ratings. Hembree, *supra*, at 3881-83, App.728-30. They alarmingly made strong recommendations based on low-quality evidence without saying whether or why they believe those recommendations satisfy GRADE criteria. *Id.*; Block, *supra*, at 2-3, App.496-97. This is advocacy—not good science.

Exemplifying this problem, one co-author acknowledged that the Endocrine Society had no data—“none”—to support Guideline 2.5, which

suggests “there may be compelling reasons to start cross-sex hormones prior to age 16” when treating gender dysphoria. Icahn Sch. of Med., *State of the Art: Transgender Hormone Care* at 5:38-6:18, YouTube (Feb. 15, 2019), https://www.youtube.com/watch?v=m7Xg9gZS_hg; Hembree, *supra*, at 3871, App.718. This change, he said, gave doctors “cover” to provide cross-sex hormones to children. *State of the Art* at 5:38-6:18. Such disregard supports his earlier boast that most in “the medical world [are] more conservative than [endocrinologists].” *Id.* at 4:33-4:38. So as one developer of evidence-based medicine has said, the Endocrine Society’s guidelines have “serious problems.” Block, *supra*, at 2, App.496.

WPATH standards also lack evidence-based support. The group admits its standards lack support from systematic reviews of available evidence and so do not rate the quality of its evidence. E. Coleman et al., *Standards of Care for the Health of Transgender and Gender Diverse People, Version 8*, 23 *Int’l J. Transgender Health* S1, S42 (2022), <https://www.wpath.org/publications/soc>. In their view, “a systematic review ... is not possible,” but a co-developer of evidence-based medicine says such reviews “are always possible,” and the group would “violat[e] standards of trustworthy guidelines” by making “a recommendation without one.” Block, *supra*, at 3, App.497. What’s more, others *have* systematically reviewed the evidence, and the results are disturbing.

2. Systematic reviews have shown insufficient evidence to use puberty blockers and cross-sex hormones to treat minors with gender dysphoria.

Many groups, including the U.K. National Institute for Health & Care Excellence, have systematically reviewed available evidence supporting the use drug intervention to treat gender-dysphoric minors and concluded it has “very low” quality under the GRADE method. *Evidence review: Gonadotrophin releasing hormone analogues for children & adolescents with gender dysphoria*, NICE (2020) (NICE I), App.307-437; *Evidence review: Gender-affirming hormones for children & adolescents with gender dysphoria*, NICE (2020) (NICE II), App.151-306. So England’s National Health Service has *stopped* using puberty blockers to treat gender-dysphoric youth in clinical settings. *Implementing advice from the Cass Review*, NHS (2023), <https://perma.cc/L2CV-M7ND>.

Swedish and Finnish authorities have also systematically reviewed the evidence and concluded its quality is insufficient to justify using puberty blockers and cross-sex hormones for children with gender dysphoria in clinical settings. *Medical treatment methods for dysphoria associated with variations in gender identity in minors – recommendation 1*, Council for Choices in Health Care in Finland (2020), App.537; *Care of children & adolescents with gender dysphoria 4*, Socialstyrelsen (2022), App.57. Denmark has also begun promoting a “developmentally-informed approach that prioritizes psychosocial support and noninvasive

resolution of gender distress” because of the “growing rates of detransition” and “profound uncertainty about long-term outcomes” in performing such “life-altering interventions.” *Denmark Joins the List of Countries That Have Sharply Restricted Youth Gender Transitions*, SEGM (Aug. 17, 2023), <https://perma.cc/D9XL-73YK>. To be sure, European nations that forbid clinical use still allow research to continue. Order at 26. But that does *not* mean drug intervention is safe—clinical research aims to benefit future patients, not those being studied. *Clinical Research Versus Medical Treatment*, FDA (2018), <https://perma.cc/8TTD-2HTP>.

Likewise, McMaster University, where evidence-based medicine originated, systematically reviewed the “[e]ffects of gender affirming therapies in people with gender dysphoria” and concluded that (1) “there is great uncertainty about the effects of puberty blockers, cross-sex hormones, and surgeries in young people with gender dysphoria” and (2) available evidence “is not sufficient to support ... using these treatments.” Romina Brignardello-Petersen & Wojtek Wiercioch, *Effects of gender affirming therapies in people with gender dysphoria: evaluation of the best available evidence* 5 (2022), App.623. The Cochrane Library agrees, finding *not a single study* sufficiently rigorous to warrant inclusion in its systematic review. C. Haupt et al., Cochrane Library, *Anti-androgen or estradiol treatment or both during hormone therapy in transitioning transgender women (Review)* (2020), App.26-47.

And this summer, 21 clinicians and researchers from nine countries warned that treating gender-dysphoric minors with puberty blockers and cross-sex hormones “is not supported by the best available evidence,” expressly criticizing “the Endocrine Society’s claims” to the contrary. Riitakerttu Kaltiala et al., *Youth Gender Transition is Pushed Without Evidence*, Wall St. J., July 13, 2023, <https://perma.cc/5P6X-KNHL>. Per this report, “[e]very systematic review of evidence to date, *including one published in the Journal of the Endocrine Society*, has found the evidence for mental-health benefits of hormonal interventions for minors to be of low or very low certainty.” *Id.* (emphasis added). “By contrast, the risks are significant and include sterility, lifelong dependence on medication and the anguish of regret.” *Id.* Indiana’s caution is warranted here.

3. Using puberty blockers and cross-sex hormones to treat minors with gender dysphoria has no proven benefits and poses substantial risk.

Despite these significant concerns, the court below credited Plaintiffs’ assertion that providing gender-dysphoric children puberty blockers and cross-sex hormones might limit “their dysphoria,” avoid “additional distress,” and improve overall mental health. Order at 25. Yet those drugs have no proven benefits and pose substantial risk.

Start with supposed benefits. No reliable evidence suggests that drug intervention reduces the risk of suicide. WPATH’s own commissioned review shows no link between the use of cross-sex hormones and

decreased suicide rates in gender-dysphoric individuals. Kellan E. Baker et al., *Hormone Therapy, Mental Health, & Quality of Life Among Transgender People: A Systematic Review*, 5:4 J. Endocrine Soc’y 1, 12 (2021), App.511. Multiple studies have also found high suicide rates before, during, and after attempted gender transition. C.M. Wiepjes et al., *Trends in suicide death risk in transgender people: results from the Amsterdam Cohort of Gender Dysphoria study (1972-2017)*, 141 Acta Psychiatrica Scandinavica 486, 490 (2020), App.52; Jay McNeil et al., *Suicide in Trans Populations: A Systematic Review of Prevalence and Correlates*, 4:3 Psychology of Sexual Orientation & Gender Diversity 341, 348 (2017), App.479; Cecilia Dhejne et al., *Long-Term Follow-Up of Transsexual Persons Undergoing Sex Reassignment Surgery: Cohort Study in Sweden*, 6:2 PLOS ONE 1, 5 (2011), App.64. And more alarmingly, a recent study found that rates of suicidal ideation, suicide attempts, and non-suicidal self-harm *increased* after minors began using puberty blockers and cross-sex hormones, Laura E. Kuper et al., *Body Dissatisfaction & Mental Health Outcomes of Youth on Gender-Affirming Hormone Therapy*, 145:4 Pediatrics 1, 8 (2020), App.533.

Likewise, no reliable evidence shows that drug intervention improves psychosocial outcomes. As the NICE systematic review found, studies showing puberty blockers and cross-sex hormones’ effect on mental health outcomes trigger “very low certainty” and suggest little or no change. NICE I, *supra*, at 13, App.319; NICE II, *supra*, at 50, App.200.

Indeed, many studies report *no* mental health improvement after such intervention. Riittakerttu Kaltiala et al., *Adolescent development and psychosocial functioning after starting cross-sex hormones for gender dysphoria*, 74:3 *Nordic J. Psychiatry* 213, 217 (2020), App.607; Annette L. Cantu et al., *Changes in Anxiety & Depression from Intake to First Follow-Up Among Transgender Youth in a Pediatric Endocrinology Clinic*, 5:3 *Transgender Health* 196, 198 (2020), App.19; Polly Carmichael et al., *Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK*, 16:2 *PLOS ONE* 1 (2021), App.576-601; Elizabeth Hisle-Gorman et al., *Mental Healthcare Utilization of Transgender Youth Before & After Affirming Treatment*, 18 *J. Sexual Med.* 1444, 1447 (2021), App.122.

Moving to risks, drug intervention may impair cognitive development. Researchers know that “the pubertal and adolescent period is associated with profound neurodevelopment,” which depends heavily on sex-specific hormones; and many academics worry that “pubertal suppression may prevent key aspects of development during a sensitive period of brain organization.” Diane Chen et al., *Consensus Parameter: Research Methodologies to Evaluate Neurodevelopmental Effects of Pubertal Suppression in Transgender Youth*, 5:4 *Transgender Health* 246, 248-249 (2020), App.72-73. So a respected research group published a “consensus

parameter” requesting more research on this issue, *id.*—a point other reviews and reports support—and noting the critical information deficit. NICE I, *supra*, at 38, App.344; Cass Review 38-39.

Next, these drug uses increase infertility risk. The Endocrine Society itself admits this. Hembree, *supra*, at 3878, App.725. Children who persist through their guidelines and take cross-sex hormones in early to mid-adolescence will lack “fertility preservation” options because they never develop fertility. Dep. of Armand H. Antommara at 207:16-209:23, *Boe v. Marshall*, No. 2:22-cv-184-LCB (M.D. Ala. Apr. 21, 2023), App.751-52. To be sure, Plaintiffs cite two studies involving a non-representative survey of females who self-reported pregnancy after taking testosterone as adults. Alexis D. Light et al., *Transgender Men Who Experienced Pregnancy After Female-to-Male Gender Transitioning*, 124:6 *Obstetrics & Gynecology* 1120, 1126 (2014), App.7; Knudson, G., & De Sutter, P., *Fertility options in transgender and gender diverse adolescents*. 96(10) *Acta obstetrica et gynecologica Scandinavica* 1269 (2017), Expert Decl. of Daniel Shumer, M.D. 19 (¶ 70), *K.C. v. The Individual Members of the Med. Licensing Bd. of Ind.*, No. 1:23-cv-00595-JPH-KMB (Apr. 21, 2023), ECF No. 26-2. But these studies do not include representative samples or adolescents who persist taking puberty blockers and cross-sex hormones. Indeed, “it is not possible for children who have not undergone natal puberty (and who may have used gender affirming hormones) to

preserve gametes.” Paula Amato, *Fertility options for transgender persons*, UCFS (June 17, 2016), <https://perma.cc/6MJD-JJ9S>. Such limited or even supportive studies hardly resolve Indiana’s concerns.

Drug intervention may also weaken bone density. For adults, osteoporosis is a “well understood” risk of using cross-sex hormones long-term. Cass Review 36. And children face added risks. Because bone mineral density increases during puberty, children undergoing puberty suppression do not experience this full increase. Hembree, *supra*, at 3882, App.729; Submission of Evidentiary Material, Ex. 27, *K.C. v. The Individual Members of the Med. Licensing Bd. of Ind.*, No. 1:23-cv-00595-JPH-KMB (June 1, 2023), ECF No. 49-10. And evidence suggests these children never catch up. *Id.*; NICE II, *supra*, at 14, App.164.

Cardiovascular decline is also a risk. As the Endocrine Society admits, evidence shows that cross-sex hormones detrimentally affect adult lipid profiles. Hembree, *supra*, at 3891, App.738. This is a “well understood” risk. Cass Review 36. NICE’s systematic review uncovered *only one* cardiovascular study of individuals who began cross-sex hormones in adolescence, and it found statistically significant increases in blood pressure and body mass for both sexes and worsening lipid profiles for natal females. NICE II, *supra*, at 14, App.164. Both the Endocrine Society and NICE say we need better studies to show how long-term use of cross-sex hormones beginning in adolescence affects cardiovascular health. Hembree, *supra*, at 3891, App.738; NICE II, *supra*, at 14, App.164.

Drug intervention may also limit sexual function. WPATH's president has reported that "about zero" natal males can achieve orgasm after undergoing early puberty suppression followed by cross-sex hormones and vaginoplasty. Michael Biggs, *The Dutch Protocol for Juvenile Transsexuals: Origins & Evidence*, J. Sex & Marital Therapy 12-13 (2022), App.566-67. While this issue needs more study, *id.*, there are substantial concerns with subjecting prepubertal children to medical treatment that may affect lifelong sexual function in ways they cannot possibly understand. Stephen B. Levine et al., *Reconsidering Informed Consent for Trans-Identified Children, Adolescents, & Young Adults*, J. Sex & Marital Therapy 15 (2022), App.704.

What's more, the long-term safety of "treatments in children and adolescents with gender dysphoria" is "largely unknown" because many identified risks tend to manifest later in life—e.g., the risk of cognitive impairment, cardiovascular decline, and osteoporosis. NICE II, *supra*, at 14, App.164. Indeed, early studies report substantial *increases* in mortality from suicide, cardiovascular events, and other problems more than ten years after drug and surgical intervention. One study found that suicide rates surged *over 19 times* the rate of controls in this population, and that mortality rates from cardiovascular disease more than doubled. Dhejne, *supra*, at 5, App.64. Another study found that adults treated with cross-sex hormones faced increased long-term risk of death by suicide, stroke, and ischemic heart disease. Henk Asscheman et al., *A long-term*

follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones, 164:4 Eur. J. Endocrinology 635, 635-42 (2011).

4. Drug companies have not sought regulatory approval for puberty blockers and cross-sex hormones to treat minors with gender dysphoria.

Given these concerns, it's no surprise that drug companies have not sought FDA approval to treat gender-dysphoric minors with hormonal interventions. Under federal law, a pharmaceutical company wanting to introduce any new drug into commerce must first obtain FDA approval. 21 U.S.C. § 355(a). If the FDA finds that the drug is safe and effective for use under conditions prescribed in proposed labeling, the pharmaceutical company can introduce the new drug into commerce using the approved labeling. *Id.* § 355(d). If the company seeks to modify its labeling to add a new use, the company must submit a new drug application seeking FDA approval for the change under the same process as the initial approval. 21 U.S.C. § 355(b); 21 C.F.R. §§ 314.54, 314.70.

Because the FDA typically limits its review to the proposed labeling, the agency does not evaluate the safety of a new drug for off-label (i.e., unapproved) uses. *Understanding Unapproved Use of Drugs "Off Label,"* U.S. Food & Drug Admin. (2018), <https://perma.cc/Y5LE-S9PZ>. While clinicians may prescribe approved drugs for off-label uses when they believe it's "medically appropriate for their patient," *id.*, a drug manufacturer may not promote off-label uses of its drug. *See* 21 C.F.R.

§ 202.1(e)(4). Many manufacturers have faced significant criminal and civil penalties for doing so. *E.g.*, Press Release, U.S. Dep't Justice, *Pfizer to Pay \$2.3 Billion for Fraudulent Marketing* (Sept. 2, 2009), <https://perma.cc/W3JG-WPBE>; Press Release, U.S. Atty's Off., *Abbott Laboratories and AbbVie Inc. to Pay \$25 Million to Resolve False Claims Act Allegations of Kickbacks and Off-Label Marketing of the Drug TriCor* (Oct. 26, 2018), <https://perma.cc/46HZ-CEPD>; Press Release, U.S. Dep't of Justice, *Endo Pharmaceuticals and Endo Health Solutions to Pay \$192.7 Million to Resolve Criminal and Civil Liability Relating to Marketing of Prescription Drug Lidoderm for Unapproved Uses* (Feb. 21, 2014), <https://perma.cc/56G5-NH7F>.

So pharmaceutical companies must decide whether it makes financial sense to seek FDA approval for off-label use. Such applications must prove that the drug is safe and effective under the proposed labeling. 21 U.S.C. § 355(d). This effort may cost companies substantial time and investment and, importantly, may reveal significant safety concerns with the new labeling. Often, companies lack financial incentive to seek such approval. That's true for AbbVie, Inc, manufacturer of the puberty blocker Lupron, which netted \$783 million from sales in 2021, *Financial Release*, AbbVie (2021), App.438-50, and for Endo Pharmaceuticals, manufacturer of the puberty blocker Supprelin, which netted over \$114 million from sales the same year. *Endo Reports Fourth-Quarter & Full-Year 2021 Financial Results*, ENDO (2022), App.130-50.

With these massive profits and little scientific support, drug companies have no incentive to seek FDA approval for using puberty blockers and cross-sex hormones to treat gender dysphoria. In fact, Endo has said it “has no plans to seek regulatory approval for the use of its drug for” this purpose. Chad Terhune et al., *As more transgender children seek medical care, families confront many unknowns*, Reuters (Oct. 6, 2022), <https://perma.cc/UYT2-GEHC>. Without regulatory approval, the Minors Protection Act protects Indiana children from becoming human experiments for off-label drug use that the FDA has never approved.

5. That puberty blockers and cross-sex hormones are used to treat different physical illness does not make them safe to treat gender dysphoria.

Plaintiffs criticize the Act for allowing puberty blockers and cross-sex hormones to treat medical issues like “precocious puberty, delayed puberty, hypogonadism,” and other physical ills but forbidding them to treat gender dysphoria. MPI 9. This distinction is not arbitrary. The Act validly distinguishes what’s safe to treat mental health conditions from what’s safe to treat physical conditions that have different etiologies, diagnostic criteria, and treatment pathways. Ignoring such distinctions would allow litigants to argue it’s safe to prescribe chemotherapy drugs to treat anxiety because doctors use them to treat cancer.

Substantial differences separate different uses of puberty blockers and cross-sex hormones. For example, central precocious puberty occurs

when a child experiences puberty earlier than normal. It is diagnosed through physical examination and laboratory testing. Melinda Chen & Erica A. Eugster, *Central Precocious Puberty: Update on Diagnosis & Treatment*, 17:4 Paediatr Drugs 273, 275 (2015), App.541. And it is treated through puberty blockers, though the patient stops these drugs in time to undergo endogenous puberty. By contrast, puberty blockers are administered for gender dysphoria *during* the normal ages for puberty, and when stopped, the child is prescribed cross-sex hormones to avoid endogenous puberty altogether. Evidentiary Material, Exs. 2 at 20, 24 & 4 at 19, *K.C. v. The Individual Members of the Med. Licensing Bd. of Ind.*, No. 1:23-cv-00595-JPH-KMB (June 1, 2023), ECF Nos. 48-2, 48-4.

Likewise, polycystic ovary syndrome occurs when females overproduce testosterone. It is diagnosed through observation, imaging, and laboratory testing, and patients are often treated with estrogen to suppress testosterone, which aims to counteract the ill effects of abnormal hormone levels. A recent study shows that treating this condition with testosterone suppression may preserve fertility otherwise impaired by abnormal testosterone levels. E. Elenis et al., *Early initiation of anti-androgen treatment is associated with increased probability of spontaneous conception leading to childbirth in women with polycystic ovary syndrome: a population-based multiregistry cohort study in Sweden*, 36:5 Human Reproduction 1427, 1433-34 (2021), App.116-17. Yet testosterone blockers

for gender dysphoria thwart fertility and normal sexual function, as explained above.

Finally, consider sexual development disorders, which expert witness Dr. Hruz routinely treats at the Washington University clinical program he co-founded. All these disorders involve objective chromosomal or physical abnormalities. Evidentiary Material, Ex. 2 at 19, *K.C. v. The Individual Members of the Med. Licensing Bd. of Ind.*, No. 1:23-cv-00595-JPH-KMB (June 1, 2023), ECF No. 48-2. When used in these situations, drug intervention helps physically unhealthy individuals develop physically healthy sexual function consistent with their sex. In stark contrast, using puberty blockers and cross-sex hormones for gender dysphoria causes physically healthy individuals to *lose* healthy sexual function consistent with their sex. That critical difference justifies Indiana's Minors Protection Act.

6. Consistent with evidence-based medicine, this Court should credit experts based mainly on their analysis of published evidence.

Plaintiffs criticize Indiana's experts for never treating "a minor patient for gender dysphoria." MPI Reply 5. But those experts use evidence-based medicine, which relies not on anecdote but on "the best available ... evidence from systematic research." David L. Sackett et al., *Evidence based medicine: what it is and what it isn't*, 312 *BMJ* 71, 71 (1996), App.68; Guyatt, *Users' Guides, supra*, at xxiv. Systematic reviews rate

evidence quality—placing randomized controlled trials at the top, and “unsystematic observations of individual clinicians” at the bottom. *Id.* at 15-16. Plaintiffs treat the *least* reliable evidence as the best.

For example, Dr. Cantor is a Ph.D. clinical psychologist and researcher with decades of experience and dozens of peer-reviewed publications. He supported his 299-paragraph expert report with citations to 199 different sources, most of which were peer-reviewed medical literature, including his own about treating gender dysphoria.

Similarly, Dr. Hruz holds an M.D. and a Ph.D. in biochemistry. He’s a board-certified pediatrician and pediatric endocrinologist with decades of clinical experience, a medical faculty appointment, and dozens of peer-reviewed publications. He supported his 95-paragraph expert report with 100 footnoted citations to medical literature. Dr. Hruz also regularly prescribes puberty blockers and cross-sex hormone, consistent with evidence-based medicine, to treat endocrinal disorders.

This Court should reject prioritizing Plaintiffs’ anecdotal evidence over this evidence-based science. Plaintiffs would have this Court override evidence-based science and declare the Minors Protection Act unconstitutional to allow experimental treatments that European countries—the world leaders in treating gender dysphoria—have concluded are inconclusive at best and harmful at worst. American kids deserve better.

II. This Court should allow state legislatures to decide this difficult medical issue rife with uncertainty and so avoid mirroring courts further in constitutionalized medicine.

“It is indisputable ‘that a State’s interest in safeguarding the physical and psychological wellbeing of a minor is compelling.’” *Otto v. City of Boca Raton*, 981 F.3d 854, 868 (11th Cir. 2020) (quoting *Ferber*, 458 U.S. at 756-57); accord *Eknes-Tucker*, 2023 WL 5344981, at *17. And States play a “significant role ... in regulating the medical profession.” *Gonzales v. Carhart*, 550 U.S. 124, 157 (2007). Here, Indiana has enacted the Minors Protection Act to safeguard children from potentially dangerous and experimental drug treatments. Section I, *supra*. Evidence strongly suggests that Indiana’s caution is warranted. *Id.* But even if both sides had “medical support for their position,” “[m]edical uncertainty does not foreclose the exercise of legislative power,” and the State may reasonably act to protect children. *Gonzales*, 550 U.S. at 161, 164.

What’s more, both sides have marshaled experts to support their positions. These experts belong to professional groups, but “their institutional positions cannot define the boundaries of” what the Constitution requires. *Otto*, 981 F.3d at 869. “They may hit the right mark,” or they may “miss it.” *Id.* And sometimes, these professional communities can be wrong “by a wide margin.” *Id.* Indeed, it’s “not uncommon for professional organizations to do an about-face in response to new evidence or new attitudes.” *Id.* That’s happened on the very issue presented here, as Euro-

pean nations are now backtracking and forbidding these drug interventions to treat children with gender dysphoria because new evidence suggests that caution is best. Section I.B.2, *supra*.

For this reason, courts give “state and federal legislatures wide discretion to pass legislation in areas where there is medical and scientific uncertainty.” *Gonzales*, 550 U.S. at 163. This restraint is both wise and constitutionally required. Take *Roe v. Wade*, 410 U.S. 113 (1973), a case in which the Court constitutionalized abortion without textual support or certainty about unborn human life. Courts then struggled for decades to apply an “inherently standardless” rule covering an issue “of great social significance.” *Dobbs v. Jackson Women’s Health Org.*, 142 S. Ct. 2228, 2272, 2284 (2022). Then just last year, the Court reversed *Roe*, admitting that precedent had “departed from [the Court’s] normal rule” of legislative deference and regretting the tremendous “turmoil” that deviation inflicted. *Id.* at 2268, 2283. This Court should avoid similar turmoil by deferring to reasonable legislative judgment here.

CONCLUSION

This Court should reverse and uphold Indiana’s right to protect children consistent with its reasonable legislative judgment.

Dated: August 28, 2023

Respectfully submitted,

/s/ John J. Bursch

JACOB P. WARNER
ALLIANCE DEFENDING FREEDOM
15100 N. 90th Street
Scottsdale, AZ 85260
(480) 444-0020
jwarner@ADFlegal.org

JOHN J. BURSCH
JAMES A. CAMPBELL
ALLIANCE DEFENDING FREEDOM
440 First Street NW
Suite 600
Washington, DC 20001
(616) 450-4235
jbursch@ADFlegal.org

Attorneys for Amicus Curiae

CERTIFICATE OF COMPLIANCE

This brief complies with the word limit of 7th Circuit Rule 29 because this brief contains 5,746 words, excluding parts of the brief exempted by Fed. R. App. P. 32(f).

This brief complies with the typeface requirements of Fed. R. App. P. 32(a)(5) and the type-style requirements of Fed. R. App. P. 32(a)(6) because this brief has been prepared in Word 365 using a proportionally spaced typeface, 14-point Century Schoolbook.

Dated: August 28, 2023

/s/ John J. Bursch

John J. Bursch

Attorney for Amicus Curiae

CERTIFICATE OF SERVICE

I hereby certify that on August 28, 2023, I electronically filed the foregoing brief with the Clerk of the Court for the United States Court of Appeals for the Seventh Circuit by using the appellate CM/ECF system. I certify that all participants in the case are registered CM/ECF users and that service will be accomplished by the CM/ECF system.

/s/ John J. Bursch

John J. Bursch

Attorney for Amicus Curiae